CellCentric’s leadership and advisory team has deep experience of drug discovery, development and commercialisation in oncology.
Chairman & CEO
Research Director & Board Member
Finance Director & Company Secretary
Director, Translational Science
Clinical Operations Director
Senior Clinical Research Associate
Investor Director & Board Member
Director, NCI-designated Sidney Kimmel Cancer Center; Chair, Dept. of Cancer Biology at Thomas Jefferson University
Regius Professor of Cancer Research, Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden Hospital
Chief Medical Officer, sponsor representative. TMC Pharma, formerly Allergan, Simbec-Orion
Senior Oncology Consultant; Former Head, Global Oncology Research, Johnson & Johnson
Toxicology Consultant. ApconiX. Previously UK Discovery Safety Director, AstraZeneca
CMC Consultant. Managing Director, Synth-Isis. Previously with OSI, Abbott
Formulation, SEDA Pharmaceutical Development Services Ltd. Formerly AstraZeneca
Clinical Research Associate. Previously Addenbrooke’s Hospital, Napp Pharmaceuticals
Clinical Research Associate. Previously Replimune, AstraZeneca, NHS.
Clinical Pharmacology and DMPK. Formerly GSK, AstraZeneca
QA/QC Consultant. Director/Owner, Cogent QA Ltd, formerly British Biotech, Abbott
Statistical Consultant. Alpha Medical Statistics, formerly AstraZeneca.
Consultant Scientist (mutation analysis), Oncognition. Previously AstraZeneca
We are driven to develop and prove a first-in-class cancer drug that delivers clear clinical benefit to patients that have limited other options.
Our drug discovery and development builds upon our deep foundation in epigenetics, and collaboration with multiple world leading researchers in the space.